Pierre Diemunsch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pierre Diemunsch has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Julien Pottecher
Pôle d’Anesthésie-Réanimation & Médecine Péri-Opératoire, Service d’Anesthésie Réanimation & Médecine Péri-Opératoire, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, 67200 Strasbourg, France
4 shared publications E. Noll
Service d’anesthésie-réanimation chirurgicale, CHU de Hautepierre, Strasbourg, France
3 shared publicationsEric Noll
Service d'Anesthésie Réanimation Chirurgicale, Hôpitaux Universitaires, Strasbourg, France
3 shared publications- Frédéric Jean Mercier
Department of Anesthesia, Hôpital Antoine-Béclère, Clamart, France
3 shared publications R Schaeffer
3 shared publicationsA. Charton
2 shared publications
Latest Publications
- Open Access
- 18 March 2020
- Published by Springer Nature in Trials
- Vol. 21 (1) , 1-13
Protocol for TRAUMADORNASE: a prospective, randomized, multicentre, double-blinded, placebo-controlled clinical trial of aerosolized dornase alfa to reduce the incidence of moderate-to-severe hypoxaemia in ventilated trauma patients
Background: Acute respiratory distress syndrome continues to drive significant morbidity and mortality after severe trauma. The incidence of trauma-induced, moderate-to-severe hypoxaemia, according to the Berlin definition, could be as high as 45%. Its pathophysiology includes the release of damage-associated molecular patterns (DAMPs), which propagate tissue injuries by triggering neutrophil extracellular traps (NETs). NETs include a DNA backbone coated with cytoplasmic proteins, which drive pulmonary cytotoxic effects. The structure of NETs and many DAMPs includes double-stranded DNA, which prevents their neutralization by plasma. Dornase alfa is a US Food and Drug Administration-approved recombinant DNase, which cleaves extracellular DNA and may therefore break up the backbone of NETs and DAMPs. Aerosolized dornase alfa was shown to reduce trauma-induced lung injury in experimental models and to improve arterial oxygenation in ventilated patients. Methods: TRAUMADORNASE will be an institution-led, multicentre, double-blinded, placebo-controlled randomized trial in ventilated trauma patients. The primary trial objective is to demonstrate a reduction in the incidence of moderate-to-severe hypoxaemia in severe trauma patients during the first 7 days from 45% to 30% by providing aerosolized dornase alfa as compared to placebo. The secondary objectives are to demonstrate an improvement in lung function and a reduction in morbidity and mortality. Randomization of 250 patients per treatment arm will be carried out through a secure, web-based system. Statistical analyses will include a descriptive step and an inferential step using fully Bayesian techniques. The study was approved by both the Agence Nationale de la Sécurité du Médicament et des Produits de Santé (ANSM, on 5 October 2018) and a National Institutional Review Board (CPP, on 6 November 2018). Participant recruitment began in March 2019. Results will be published in international peer-reviewed medical journals. Discussion: If early administration of inhaled dornase alfa actually reduces the incidence of moderate-to-severe hypoxaemia in patients with severe trauma, this new therapeutic strategy may be easily implemented in many clinical trauma care settings. This treatment may facilitate ventilator weaning, reduce the burden of trauma-induced lung inflammation and facilitate recovery and rehabilitation in severe trauma patients. Trial registration: ClinicalTrials.gov, NCT03368092. Registered on 11 December 2017.
- 18 March 2020
- Published by Springer Nature in Trials
- Vol. 21 (1) , 1-13
Open AccessProtocol for TRAUMADORNASE: a prospective, randomized, multicentre, double-blinded, placebo-controlled clinical trial of aerosolized dornase alfa to reduce the incidence of moderate-to-severe hypoxaemia in ventilated trauma patients
Background: Acute respiratory distress syndrome continues to drive significant morbidity and mortality after severe trauma. The incidence of trauma-induced, moderate-to-severe hypoxaemia, according to the Berlin definition, could be as high as 45%. Its pathophysiology includes the release of damage-associated molecular patterns (DAMPs), which propagate tissue injuries by triggering neutrophil extracellular traps (NETs). NETs include a DNA backbone coated with cytoplasmic proteins, which drive pulmonary cytotoxic effects. The structure of NETs and many DAMPs includes double-stranded DNA, which prevents their neutralization by plasma. Dornase alfa is a US Food and Drug Administration-approved recombinant DNase, which cleaves extracellular DNA and may therefore break up the backbone of NETs and DAMPs. Aerosolized dornase alfa was shown to reduce trauma-induced lung injury in experimental models and to improve arterial oxygenation in ventilated patients. Methods: TRAUMADORNASE will be an institution-led, multicentre, double-blinded, placebo-controlled randomized trial in ventilated trauma patients. The primary trial objective is to demonstrate a reduction in the incidence of moderate-to-severe hypoxaemia in severe trauma patients during the first 7 days from 45% to 30% by providing aerosolized dornase alfa as compared to placebo. The secondary objectives are to demonstrate an improvement in lung function and a reduction in morbidity and mortality. Randomization of 250 patients per treatment arm will be carried out through a secure, web-based system. Statistical analyses will include a descriptive step and an inferential step using fully Bayesian techniques. The study was approved by both the Agence Nationale de la Sécurité du Médicament et des Produits de Santé (ANSM, on 5 October 2018) and a National Institutional Review Board (CPP, on 6 November 2018). Participant recruitment began in March 2019. Results will be published in international peer-reviewed medical journals. Discussion: If early administration of inhaled dornase alfa actually reduces the incidence of moderate-to-severe hypoxaemia in patients with severe trauma, this new therapeutic strategy may be easily implemented in many clinical trauma care settings. This treatment may facilitate ventilator weaning, reduce the burden of trauma-induced lung inflammation and facilitate recovery and rehabilitation in severe trauma patients. Trial registration: ClinicalTrials.gov, NCT03368092. Registered on 11 December 2017.
- 1 August 2019
- Published by Wolters Kluwer Health in European Journal of Anaesthesiology
- Vol. 36 (8) , 555-556
Acupressure and quality of recovery
- 1 August 2019
- Published by Wolters Kluwer Health in European Journal of Anaesthesiology
- Vol. 36 (8) , 555-556
Acupressure and quality of recovery
- Top Cited PapersOpen Access
- 1 January 2019
- Published by Elsevier in Annals of Intensive Care
- Vol. 9 (1) , 1-7
Experts’ guidelines of intubation and extubation of the ICU patient of French Society of Anaesthesia and Intensive Care Medicine (SFAR) and French-speaking Intensive Care Society (SRLF)
- 1 January 2019
- Published by Elsevier in Annals of Intensive Care
- Vol. 9 (1) , 1-7
Top Cited PapersOpen AccessExperts’ guidelines of intubation and extubation of the ICU patient of French Society of Anaesthesia and Intensive Care Medicine (SFAR) and French-speaking Intensive Care Society (SRLF)
- Open Access
- 11 July 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (7) , e0199369
Prevention of laparoscopic surgery induced hypothermia with warmed humidified insufflation: Is the experimental combination of a warming blanket synergistic?
Maintaining normothermia during anesthesia is imperative to provide quality patient care and to prevent adverse outcomes. Prolonged laparoscopic procedures have been identified as a potential risk factor for hypothermia, due to continuous insufflation of cold and dry carbon dioxide. Perioperative hypothermia is associated with increased hospital cost and many complications including; impaired drug metabolism, impaired immune function, cardiac morbidity, shivering, coagulopathy. In this experimental study, four pigs underwent four interventions each, resulting in 16 total trials. Using standardized general anesthesia in a randomized Latin-square sequence the four interventions include: 1. Control group without an administered pneumoperitoneum, 2. Administered standard pneumoperitoneum using 21°C insufflated gas and under-body forced-air warming, 3. Administered pneumoperitoneum with insufflation of warmed/humidified carbon dioxide, 4. Administered pneumoperitoneum with insufflation of warmed/humidified carbon dioxide and under-body forced-air warming. The primary outcome was distal esophageal temperature change 4 hours after trocar insertion. Four hours after trocar insertion, pigs in the control group lost 2.1 ± 0.4°C; pigs with warmed and humidified insufflation lost 1.8 ± 0.4°C; pigs with forced-air warming group lost 1.3 ± 0.9°C; and pigs exposed to a combination of warmed and humidified insufflation with forced-air warming increased by 0.3 ± 0.2°C. This experimental animal study provides evidence that a combination of warmed and humidified insufflation of carbon dioxide (CO2) in conjunction with forced-air warming is an effective strategy in the prevention of perioperative hypothermia. Further clinical trials investigating humans are therefore indicated.
- 11 July 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (7) , e0199369
Open AccessPrevention of laparoscopic surgery induced hypothermia with warmed humidified insufflation: Is the experimental combination of a warming blanket synergistic?
Maintaining normothermia during anesthesia is imperative to provide quality patient care and to prevent adverse outcomes. Prolonged laparoscopic procedures have been identified as a potential risk factor for hypothermia, due to continuous insufflation of cold and dry carbon dioxide. Perioperative hypothermia is associated with increased hospital cost and many complications including; impaired drug metabolism, impaired immune function, cardiac morbidity, shivering, coagulopathy. In this experimental study, four pigs underwent four interventions each, resulting in 16 total trials. Using standardized general anesthesia in a randomized Latin-square sequence the four interventions include: 1. Control group without an administered pneumoperitoneum, 2. Administered standard pneumoperitoneum using 21°C insufflated gas and under-body forced-air warming, 3. Administered pneumoperitoneum with insufflation of warmed/humidified carbon dioxide, 4. Administered pneumoperitoneum with insufflation of warmed/humidified carbon dioxide and under-body forced-air warming. The primary outcome was distal esophageal temperature change 4 hours after trocar insertion. Four hours after trocar insertion, pigs in the control group lost 2.1 ± 0.4°C; pigs with warmed and humidified insufflation lost 1.8 ± 0.4°C; pigs with forced-air warming group lost 1.3 ± 0.9°C; and pigs exposed to a combination of warmed and humidified insufflation with forced-air warming increased by 0.3 ± 0.2°C. This experimental animal study provides evidence that a combination of warmed and humidified insufflation of carbon dioxide (CO2) in conjunction with forced-air warming is an effective strategy in the prevention of perioperative hypothermia. Further clinical trials investigating humans are therefore indicated.
- 6 May 2017
- Published by Springer Nature
- p. 85-93
General Anaesthesia for Caesarean Section
- 1 November 2015
- Published by Wolters Kluwer Health in European Journal of Anaesthesiology
- Vol. 32 (11) , 822-823
Urapidil versus nicardipine in preeclamptic toxaemia
- 1 November 2015
- Published by Wolters Kluwer Health in European Journal of Anaesthesiology
- Vol. 32 (11) , 822-823
Urapidil versus nicardipine in preeclamptic toxaemia
- 1 May 2015
- Published by Georg Thieme Verlag KG in Journal Club AINS
- Vol. 4 (02) , 70
Sectio caesarea: HES vs. Ringerlaktat
Um Hypotension während der Spinalanästhesie zu vermeiden, wird bei elektiven Sectio caesarea die Gabe von Vasopressoren empfohlen. Eine Gruppe hat untersucht, ob dabei die Gabe von Hydroxyethylstärke (HES) oder Ringerlaktat effektiver und sicherer ist.
- 1 May 2015
- Published by Georg Thieme Verlag KG in Journal Club AINS
- Vol. 4 (02) , 70
Sectio caesarea: HES vs. Ringerlaktat
Um Hypotension während der Spinalanästhesie zu vermeiden, wird bei elektiven Sectio caesarea die Gabe von Vasopressoren empfohlen. Eine Gruppe hat untersucht, ob dabei die Gabe von Hydroxyethylstärke (HES) oder Ringerlaktat effektiver und sicherer ist.
- 1 February 2014
- Published by Wolters Kluwer Health in Survey of Anesthesiology
- Vol. 58 (1)
Intraperitoneal Nebulization of Ropivacaine for Pain Control After Laparoscopic Cholecystectomy
- 1 February 2014
- Published by Wolters Kluwer Health in Survey of Anesthesiology
- Vol. 58 (1)
Intraperitoneal Nebulization of Ropivacaine for Pain Control After Laparoscopic Cholecystectomy
- Open Access
- 10 October 2013
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 11 (1) , 268
First report of granulomatous mastitis associated with Sjögren’s syndrome
Granulomatous mastitis is a rare and often considered as idiopathic disease. However, clinical examination and thorough diagnostic investigations have to be carried out in order to identify cases that are secondary to infections or systemic diseases since these forms may be cured with appropriate etiologic treatment. To the best of our knowledge, this report is the first to describe the association of granulomatous mastitis with Sjögren’s syndrome. We discuss the clinical, pathological and therapeutic implications of this association.
- 10 October 2013
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 11 (1) , 268
Open AccessFirst report of granulomatous mastitis associated with Sjögren’s syndrome
Granulomatous mastitis is a rare and often considered as idiopathic disease. However, clinical examination and thorough diagnostic investigations have to be carried out in order to identify cases that are secondary to infections or systemic diseases since these forms may be cured with appropriate etiologic treatment. To the best of our knowledge, this report is the first to describe the association of granulomatous mastitis with Sjögren’s syndrome. We discuss the clinical, pathological and therapeutic implications of this association.